The European LeukemiaNet Minimal Residual Disease Working Party recommended applying a comprehensive panel, including progenitor cell markers (CD34, CD117), myeloid and monocytic lineage markers, and differentiation antigens (CD2, CD7, CD19, or CD56), as well as using a different-from-normal (DfN) approach and automated data analysis testing for optimization of MFC to establish MRD in AML [29,102]. This evidence concerns the gene CD34 and acute myeloid leukemia.